eligibility_summary
Inclusion: endometrial carcinoma/carcinosarcoma, evaluable disease (RECIST 1.1), prior platinum and anti‑PD‑1/PD‑L1. Exclusion: neuroendocrine or pure sarcomas, severe ocular surface disease, active/prior IBD, recurrence >12 mo post‑curative platinum without platinum rechallenge, >3 prior lines, hx/current ILD/pneumonitis requiring steroids, prior 3rd‑line nonplatinum chemo, prior TROP2 or topo I ADCs, prior single‑agent paclitaxel & doxorubicin, recurrent effusion drainage within 6 wks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized trial in post-platinum, post-immunotherapy endometrial cancer compares: 1) Sacituzumab tirumotecan (MK-2870/SKB264): a TROP2-directed antibody–drug conjugate (ADC). Mechanism: monoclonal antibody binds TROP2 on tumor epithelial cells, internalizes, and releases a camptothecin-class topoisomerase I–inhibiting payload, causing DNA replication stress, single-strand breaks, and apoptosis (with potential bystander killing). 2) Physician’s choice chemotherapy: doxorubicin (anthracycline, DNA intercalation and topoisomerase II inhibition, ROS generation) or paclitaxel/nab-paclitaxel (taxanes, microtubule stabilization leading to mitotic arrest). Targets/pathways: TROP2-expressing tumor cells, topo I–mediated DNA repair, topo II, and microtubule dynamics.